Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Prostate Cancer
Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study

February 9, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time February 09, 2023
arrow
Moffitt Cancer Center at International Plaza
News | Proton Therapy
IBA Announces Contract with Moffitt Cancer Center for a Proteus ONE Proton Therapy Solution

February 7, 2023 — IBA (Ion Beam Applications S.A.), a world leader in particle accelerator technology, today announces ...

Time February 07, 2023
arrow
News | Contrast Media
Efficacy and Safety of Gadopiclenol with Contrast-enhanced MRI of the Central Nervous System Published

February 6, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a ...

Time February 06, 2023
arrow
Summary of the pilot study and preliminary PET imaging findings. Image created by R Wetherill, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
News | PET Imaging
PET Imaging Shows Greater Lung Inflammation in e-cigarette Users than Cigarette Smokers

January 31, 2023 — Electronic cigarette (e-cigarette) users have greater lung inflammation than cigarette smokers and ...

Time January 31, 2023
arrow
Summary of imaging findings from the SEER-Medicare linked database for patients with non-small cell lung cancer prior to receiving subsequent radiation therapy. Image created by Emily Sterbis, MD, Interventional Radiology Resident at the University of Colorado
News | Lung Imaging
Nearly Half of Medicare Patients with Non-small Cell Lung Cancer not Staged According to National Guidelines

January 23, 2023 — A study published in the January issue of The Journal of Nuclear Medicine reports that approximately ...

Time January 23, 2023
arrow
ASNC releases comprehensive tool for assessing quality, setting meaningful goals, improving patient care in SPECT MPI laboratories
News | Cardiac Imaging
New Guide Will Change How Cardiac Imagers Approach Quality Improvement

January 13, 2023 — Nuclear stress testing performed with single-photon emission computed tomography (SPECT) is the most ...

Time January 13, 2023
arrow
Proprietary electron accelerator technology achieves “two beams on target” milestone, validating proof of concept for large-scale U.S. Mo-99 production without the use of uranium
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)

January 11, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time January 11, 2023
arrow
StreamlineMD has provided updates for 2023 Radiology and IR CPT coding, which may impact your practice’s coding, billing, and reimbursement operations.
News | Radiology Business
A Look at the Changes in 2023 to Radiology and IR CPT Codes

January 5, 2023 — StreamlineMD has provided updates for 2023 Radiology and IR CPT coding, which may impact your practice ...

Time January 05, 2023
arrow
This figure highlights 3 patients with a final diagnosis of low-grade uptake (Perugini grade-1). Endomyocardial biopsy results were available for the patient depicted in Panel B demonstrating ATTR-CA as the underlying pathology.
News | Molecular Imaging
Nuclear Medicine Bone Scan Study Identifies Prevalence and Outcomes of Cardiac Amyloidosis

January 5, 2023 — A new study has determined that approximately three percent of all bone scan patients have markers of ...

Time January 04, 2023
arrow
 IBA, a world leader in particle accelerator technology, today confirms that it has signed a contract with the Spanish Ministry of Health to install ten proton therapy systems across Spain as part of a significant public tender.
News | Proton Therapy
IBA Wins 10 Proton Therapy System Contract in Spain

January 2, 2023 — IBA, a world leader in particle accelerator technology, today confirms that it has signed a contract ...

Time January 02, 2023
arrow
Patients for Safer Nuclear Medicine calls NRC ruling a victory, notes work to protect patients is not over
News | Nuclear Imaging
Patient Coalition Applauds Federal Decision Impacting Nuclear Medicine Safety

January 2, 2023 — The federal agency that oversees the administration of nuclear medicine has announced that it will ...

Time January 02, 2023
arrow
Abhinav Jha to develop technique, test in patients with metastatic prostate cancer
News | Radiation Therapy
Imaging Technique May Measure Absorbed Dose from Radiation Therapy

December 22, 2022 — Patients with cancer that has spread to the bone are sometimes treated with alpha particle radiation ...

Time December 22, 2022
arrow
data showed that CytoSite’s Granzyme B (GzmB) PET imaging using [68Ga-NOTA]-hGZP (CSB-111) was feasible and safe in human subjects. These data come from a Phase I trial assessing the safety and feasibility of GzmB PET imaging in subjects with melanoma and non-small cell lung cancer (NSCLC) receiving KEYTRUDA (pembrolizumab).
News | Clinical Trials
CytoSite Bio Presents First-in-Human Data at Radiological Society of North American Annual Meeting

December 14, 2022 — CytoSite Bio, a company developing precision imaging products that determine patient response to ...

Time December 14, 2022
arrow
18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Prostate Cancer
Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

December 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time December 02, 2022
arrow
A team led by UTHealth Houston's K. Lance Gould, MD, (center) used PET imaging technology (shown above) to map coronary blood flow and its outcomes among heart disease patients. (Photo by UTHealth Houston)
News | PET Imaging
PET Technology More Effective Than Angiogram at Determining Need for Coronary Stents, Bypass Surgery

December 1, 2022 — A new method for determining whether patients with heart disease need coronary stents or bypass ...

Time December 01, 2022
arrow
Researchers at the University of Wisconsin–Madison will kick off research scanning human subjects with GE Healthcare’s latest generation PCCT prototype in December 2022, representing the first U.S. clinical evaluation site with GE Healthcare’s pure silicon CT detector technology
News | Proton Therapy
UW–Madison To Perform the First U.S. Evaluation of GE Healthcare’s Photon Counting CT Technology with Deep Silicon Detectors

November 25, 2022 — Researchers at the University of Wisconsin–Madison, the first U.S. clinical evaluation site for GE ...

Time November 25, 2022
arrow
Simulations by Rice University engineers have revealed details about the molecular interactions between gadolinium contrast agents used in MRI scans and their liquid environment. In this model, green gadolinium is surrounded by blue chelate ions, themselves surrounded by water (gray oxygen and red hydrogen atoms). Thiago Pinheiro dos Santos/Rice University
News | Magnetic Resonance Imaging (MRI)
Rice Refines Analysis of MRI Contrast Agents

November 21, 2022 — You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering ...

Time November 21, 2022
arrow
Figure 1. The fat pad adjacent to the kneecap (Hoffa's fat pad, infrapatellar fat pad) can change in signal on MRI when the knee is inflamed. (A) Normal knee without signs of inflammation. (B) Arrow pointing on a circumscribed area with higher signal (bright lines) in the area of the fat pad (normally dark), which is indicative of a beginning inflammatory reaction. (C) The whole fat pad has a higher signal (light grey color with white lines), which is a sign of progressive inflammation of the knee joint.
News | RSNA
NSAIDs May Worsen Arthritis Inflammation

November 21, 2022 — Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen ...

Time November 21, 2022
arrow
NorthStar Medical Radioisotopes’ Radiopharmaceutical CDMO in Beloit, Wis. (artist rendering). Upon completion, NorthStar will be first and only U.S. company housing commercial-scale, multi-radioisotope production and radiopharmaceutical development services on the same campus, enabling collaborating companies to realize logistical, regulatory and cost benefits. (Photo: Business Wire)
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Expands Business Platform with New, Patient-focused, Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) Services Unit

November 15, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time November 15, 2022
arrow
The American Society of Nuclear Cardiology has issued an alert about possible supply disruptions
News | Radiopharmaceuticals and Tracers
Alert: Mo-99/Tc-99m Supply Disruptions Possible

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Time November 05, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now